Adma Biologics ADMA
NASDAQ ADMA
$12.79 +0.06 (+0.47%)
At close: Nov 9, 2026 · 4:00 PM EST

Adma Biologics (ADMA) Gains (Losses) on Sale of Assets & Investments (2011 - 2026)

Updated

Analysis

Adma Biologics (ADMA) Gains (Losses) on Sale of Assets & Investments (2011 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn -
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn -
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn -
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn -
5 Novartis Ag 316.85 Bn 290.09 Bn - -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn -
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn -
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn -
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn -
10 Adma Biologics 2.87 Bn 2.39 Bn 99.92 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 7.98 Mn
Mar 31, 2019 11.53 Mn
Jun 30, 2011 -1.33 Mn
Mar 31, 2011 605,297.00
API Access

Adma Biologics Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=ADMA&period=max&api_key=YOUR_API_KEY